Altamira Therapeutics (CYTO) H2 2025 earnings summary

Executive summary

• Expanded nucleic acid delivery business with new applications, including GenePhore for DNA delivery and further development of the xPhore platform.

• Advanced plans for the spin-off of the nucleic acid delivery business and continued strategic repositioning.

• Achieved milestones in associate Medica's Bentrio nasal spray, including EU MDR clearance and China marketing approval.

Financial highlights

• Total operating loss from continuing operations decreased to $4.4 million in 2025 from $6.9 million in 2024.

• Research and development expenses fell to $2.0 million in 2025 from $3.7 million in 2024; G&A expenses decreased to $2.6 million from $3.2 million.

• Net finance income of $1.2 million in 2025 versus a net finance expense of $0.8 million in 2024.

• Net loss for 2025 was $3.0 million, improved from $8.5 million in 2024; loss per share $0.55 vs. $2.99.

• Shareholders' equity was $3.0 million at year-end 2025, down from $6.6 million at year-end 2024.

Outlook and guidance

• Operating expenses expected to decrease significantly in 2026 following the planned spin-off and SEC deregistration.

• Financial guidance will be updated as material new information becomes available.